Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: Possible implications of glial cells

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 53-65

  Nagatsu, T ^a,b   Sawada, M ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; 1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALDEHYDE; ALPHA TOCOPHEROL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROGEN PEROXIDE; LAZABEMIDE; LEVODOPA; MANGANESE SUPEROXIDE DISMUTASE; MONOAMINE OXIDASE B INHIBITOR; NERVE GROWTH FACTOR; NEUROMELANIN; NEUROTROPHIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; PYRIDINIUM DERIVATIVE; RASAGILINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; THIOREDOXIN; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR;

CATALYSIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LOCALIZATION; FENTON REACTION; GLIA CELL; HUMAN; MOLECULAR MECHANICS; MONOTHERAPY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; OXIDATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 34248524384     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_7     Document Type: Review

References (153)

1. Abell CW, Kwan SW (2001) Molecular characterization of monoamine oxidase A and B. Prog Nucleic Acid Mol Biol 65: 129-156
2. Andoh T, Chock PB, Chiueh CC (2002) The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J Biol Chem 277: 9655-9660
3. Ando T, Chock PB, Murphy DL, Chiueh CC (2005) Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol Pharmacol on line publication: 12 August 2005
4. Arai R, Kimura H, Nagatsu I, Maeda T (1997) Preferential localization of monoamine oxidase type A in neurons of the locus coeruleus and type B activity in neurons of the dorsal raphe nucleus of the rat: a detailed enzyme histochemical study. Brain Res 745: 352-356
5. Arai R, Horiike K, Hasegawa Y (1998) Dopamine-degrading activity of monoamine oxidase is not detected by histochemistry in neurons of the substantia nigra pars compacta. Brain Res 812: 275-278
6. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Nat Acad Sci USA 85: 4934-4938
7. Berry MD, Juorio AV, Peterson IA (1994) The functional role of monoamine oxidase A and B in the mammalian central nervous system. Progr Neurobiol 42: 375-391
8. Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306
9. Binda C, Mattevi A, Edmondson DE (2002a) Structure-function relationship in flavoenzyme-dependent amine oxidase. J Biol Chem 277: 23973-23976
10. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A (2002b) Structure of human monoamine oxidase B a drug turget for the treatment of neurological disorders. Nat Struct Biol 9: 22-26
11. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to madopar® treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113-127
12. Bond PA, Cundall RL (1977) Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta 80: 317-326
13. Brabeck C, Pfeiffer R, Leake A, Beneke S, Meyer R, Buerkle A (2003) L-Selegiline potentiates the cellular poly(ADP-ribosyl)ation: Response to ionized radiation. J Pharmacol Exper Ther 306: 973-979
14. Bringmann G, Brueckner R, Muenchbach M, Feineis D, God R, Wesemann W, Grote C, Herderich M, Diem S, Lesch KP, Moessner R, Storch A (2000) "TaClo", a chloral-derived mammalian alkaloid with neurotoxic properties. In: Storch A, Collins MA (eds) Neurotoxic factors in Parkinson's disease and related disorders. Kluwer Academic Publishing/Plenum, New York, pp 145-149
15. Calne DB, Langston JW (1983) Aetiology of Parkinson's disease. Lancet 2: 1457-1459
16. Caparros-Lefebvre D, Elbaz A, The Caribbean Parkinsonism Study Group (1999) Possible relation of atypical parkinsonism in French West Indies with consumption of tropical plants: A case-control study. Lancet 354: 281-285
17. Cesura AM, Gottowik J, Lang G, Malherbe P, Da Prada MJ (1998) Structure-function relationships of mitochondrial monoamine oxidase A and B: chimaeric enzymes and site-directed mutagenesis studies. J Neural Transm [Suppl 52]: 189-2000
18. Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang H, Brealfield XO, Craig I, Hsu YPP (1991) Structure of the human gene for monoamine oxidase type A. Nucleic Acids Res 19: 4537-4541
19. Chen ZY, Powell JF, Hsu YPP, Breakfield XO, Craig IW (1992) Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genomics 14: 75-82
20. Chen K, Wu HF, Shih JC (1993) The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem 61: 187-190
21. Chen K, Shih JC (1998) Monoamine oxidase A and B: structure, function, and behavior. Adv Pharmacol 42: 292-296
22. Collins GGS, Sandler M, Williams ED, Youdim MBH (1970) Multiple forms of human brain mitochondrial monoamine oxidase. Nature 225: 817-820
23. Collins MA, Neafsey EJ (2000) Beta-carboline analogues of MPP+ as environmental neurotoxins. In: Storch A, Collins MA (eds) Neurotoxic factors in Parkinson's disease and related disorders. Kluwer Academic Publishing/Plenum, New York, pp 115-130
24. Cookson MR (2005) The biochemistry of Parkinson's disease. Ann Rev Biochem 74: 29-52
25. Counsell C (1998) Effect of adding selegiline to levodopa in early, mild Parkinson's disease: formal systematic review of data on patients in all relevant trials is required. Brit Med J 317: 1586
26. Davis GCB, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254
27. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet: 1219-1220
28. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implicatios of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Parkinson's disease: From basic research to treatmant. Adv Neurol Vol. 60, Raven Press, New York, pp 273-281
29. Donnelly CH, Richelson E, Murphy DL (1976) Properties of monoamine oxidase in mouse neuroblastoma NIE-115 cells. Biochem Pharmacol 25: 1639-1643
30. Donnelly CH, Murphy DL (1977) Substrate and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26: 853-858
31. Edmondson DE, Binda C, Mattevi A (2004) The FAD binding sites of human monoamine oxidases A and B. Neuro Toxicology 25: 63-72
32. Egashira T, Yamanaka Y (1981) Further studies on the synthesis of A-form of MAO. Jap J Pharmacol 31: 763-770
33. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49: 1-20
34. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schlyer Christian D, Wolf AP, Pappaas N, Alexoff D, Shea C, Dorfinger E, Kruchowy L, Yoo K, Fazzini E, Patlak C (1994) Slow recovery of human brain MAO-B after deprenyl (selegiline withdrawal). Synapse 18: 86-93
35. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor RR (1996) Inhibition of MAO B in the brain of smokers. Nature 379: 733-735
36. Fowler JS, Volkow ND, Wang GJ, Pappas N, Shea C, MacGregor RR (1998) Visualization of monoamine oxidase in human brain. Adv Pharmacol 42: 304-307
37. Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226: 97-108
38. rd edn. Springer, Wien New York
39. Gomes B, Naguwa G, Kloepfer HG, Yasunobu KT (1969) Amine oxidase XV. The sulfhydryl groups of beef liver mitochondrial amine oxidase. Arch Biochem Biophys 132: 28-33
40. Green AR, Mitchell BD, Tordoff AF, Youdim MBH (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60: 343-349
41. Grimsby J, Lan NC, Neve R, Chen K, Shih JC (1990) Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem 55: 1166-1169
42. Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC (1991) Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Nat Acad Sci USA 88: 3637-3641
43. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson's disease: Is ther a causal link? Exper Neurol 193: 279-290
44. Harada M, Nagatsu T (1969) Identification of flavin in the purified beef liver mitochondrial monoamine oxidase. Experientia 25: 538-534
45. Harada M, Mizutani K, Nagatsu T (1971) Purification and properties of mitochondrial monoamine oxidase in beef brain. J Neurochem 18: 559-569
46. Hawkins M Jr, Breakfield XO (1978) Monoamine oxidase A and B in cultured cells. J Neurochem 30: 1391-1397
47. Hida T, Hasegawa Y, Arai R (1999) Histochemical study of dopamine-degrading monoamine oxidase activity in dopaminergic neurons of rat brain. Brain Res 842: 491-495
48. Hirata Y, Sugimura H, Takei H, Nagatsu T (1986) The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices. Brain Res 397: 341-344
49. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and alminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56: 446-451
50. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 991: 214-228
51. Hornykiewicz O (2001) Dopamine and Parkinson's disease: A possible personal view of the past, the present, and the future. In: Calne D, Calne SM (eds) Parkinson's disease. Adv Neurol Vol. 86, Lippincott Williams & Wilkins, Philadelphia, pp 1-11
52. Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF (1988) Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem 51: 1321-1324
53. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105: 891-902
54. Imamura K, Nishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106: 518-526
55. Imamura K, Hishikawa N, Ono K, Suzuki H, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2005) Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropatholo 109: 141-150
56. Ito A, Kuwahara T, Inadome S, Sagara Y (1988) Molecular cloning of a cDNA for rat liver monoamine oxidase B. Biochem Biophys Res Commun 157: 970-976
57. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K (2004) Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329: 593-559
58. Jahung JW, Houpt TA, Wessel TC, Chen K, Shih JC (1997) Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 25: 30-36
59. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D, Youdim MBH (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59: 1168-1171
60. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285-1287
61. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608
62. Kitahama K, Maeda T, Denney RM, Jouvet M (1994) Monoamine oxidase: distribution in the cat brain studied by enzyme- and immunohistochemistry: recent progress. Progr Neurobiol 42: 53-78
63. Knoll J (1980) Monoamine oxidase chemistry and pharmacologly. In: Sandler M (ed) Enzyme inhibitors as drugs. Macmillan, London, pp 151-173
64. Knoll J, Magyar K (1972) Some puzzling pharmacological effect of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393-408
65. Knoll J, Yoneda F, Knoll B, Ohde H, Mikulia I (1999) (-)1-(Benzofuran-2- yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Brit J Pharmacol 128: 1723-1732
66. Kochersperger LM, Parker EL, Siciliano M, Darlington GJ, Denney RM (1986) Assignment of genes for human monoamine oxidase A and B to the X chromosomes. J Neurosci Res 16: 601-616
67. Konradi C, Svoma E, Jellinger K, Riederer P, Denney R, Thibault J (1988) Tipographic Immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26: 791-802
68. Konradi C, Kornhuber J, Froelich L, Fritze J, Heisen H, Beckmann H, Schultz E, Riederer P (1989) Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 33: 383-400
69. Kontkanen O, Castren E (1999) Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res 829: 190-192
70. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M (1995) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF. J Neurochem 65: 2633-2636
71. Kotake Y, Tasaki Y, Hirobe M, Ohta S (1998) Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4- tetrahydroisoquinoline, in mice: In vivo and in vitro studies. Brain Res 787: 341-343
72. Kosaka K (2002) Lewy body disease. Neuropathol 20 [Suppl]: 73-78
73. Kwan SW, Abell CW (1992) cDNA cloning and sequencing of rat monoamine oxidase A: comparison with the human and bovine enzymes. Comp Biochem Physiol 102B: 143-147
74. Lan NC, Heinzmann C, Gal A, Klisak I, Orth U, Lai E, Grimsby J, Sparkes RS, Mohandas T, Shih JC (1989) Human monoamine oxidase A and B genes map to Xp11.23 and are deleted in a patient with Norrie Disease. Genomics 4: 552-559
75. Lang AE, Lees AJ (2002) MAO-B inhibitors for the treatment of Parkinson's disease. Mov Disord 17 [Suppl 4]: S38-S44
76. Langston JW, Ballard P, Tetrad JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
77. Lees AJ on behalf of the Parkinson's Disease Research Group of the United Kingdom (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease. Brit Med J 311: 1602-1607
78. Leonard N, Lambert C, Depiereux E, Wouters J (2004) Modeling of human monoamine oxidase A: from low resolution threading models to accurate comparative models based on crystal structures. NeuroToxicology 25: 47-61
79. Levitt P, Pinter JE, Breakefield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79: 6385-6389
80. Levy ER, Powell JF, Buckle VJ, Hsu YP, Breakfield XO, Graig IW (1989) Localization of human monoamine oxidase-A gene to Xp11.23-11.4 by in situ hybridization: implication for Norrie disease. Genomics 5: 368-370
81. Luque JM, Kwan SW, Abell CW, Da Prada M, Richards GJ (1995) Cellular expression of mRNAs encoding monoamine oxidase A and B in the rat central nervous system. J Comp Neurol 363: 665-680
82. Luque JM, Biou V, Nicholls JG (1998) Three-dimensional visualization of the distribution, growth, and regeneration of monoaminergic neurons in whole mounts of immature mammalian CNS. J Compar Neurol 390: 427-438
83. Maruyama W, Yi H, Takahashi T, Shimazu S, Ohde H, Yoneda F, Iwase K, Naoi M (2004) Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenus dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sci 75: 107-117
84. Matsubara K (2000) N-Methyl-beta-carbonium neurotoxins in Parkinson's disease. In: Storch A, Collins MA (eds) Neurotoxic factors in Parkinson's disease and related disorders. Kluwer Academic Publishing/Plenum, New York, pp 131-143
85. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's disease and Alzheimer's disease brain. Neurology 38: 1285-1291
86. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 21: 195-218
87. McNaught KS, Jenner P (1997) Altered glia function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium-and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73: 2469-2476
88. Mena MA, de Bernardo S, Casarejos MJ, Canals S, Rodriguez-Martin E (2002) The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 25: 245-263
89. Minamiura N, Yasunobu KT (1978) Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD. Arch Biochem Biophys 189: 481-489
90. Mizuno Y, Hoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsubayashi S, Matsumine H, Kondo T (1998) Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 44 [Suppl 1]: S99-S109
91. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S (2000) Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 279: 751-755
92. Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinsonian brain. J Neural Transm 72: 77-81
93. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994a) Tumor necrosis factor-alpha (TNF-alpha) increases in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208-210
94. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994b) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150
95. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999a) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270: 45-48
96. Mogi M, Nagatsu T (1999b) Neurotrophins and cytokines in Parkinson's disease. In: Stern G (ed) Parkinson's disease: Adv Neurol Vol. 80, Lippincott Williams & Wilkins, Philadelpha, pp 135-139
97. Moser A, Koempf D (1992) Presence of methyl-6,7-dihydroxy-1,2,3,6- tetrarahydroisoquinoline derives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. Life Sci 50: 1885-1891
98. Murphy DL, Donnelly CH, Richelson E (1976) Substrate and inhibition-related characteristics of monoamine oxidase in C6 rat glioma cells. J Neurochem 26: 1231-1235
99. Nagatsu T (1993) Biochemical aspects of Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Parkinson's disease: From basic research to treatment. Adv Neurol Vol. 60, Raven Press, New York, pp 165-174
100. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29: 99-111
101. Nagatsu T (2002a) Parkinson's disease: changes in apoptosis-relating factors suggesting possible gene therapy. J Neural Transm 109: 731-745
102. Nagatsu T (2002b) Amine-related neurotoxins in Parkinson's disesase: Past, present, and future. Neurotoxicology and Teratology 24: 565-569
103. Nagatsu T (2004) Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neuro Toxicology 25: 11-20
104. Nagatsu T, Nakano T, Kato T, Higashida H (1981) Expression of A and B types of monoamine oxidase in neuroblastoma hybrid cells. Neurochem Int 3: 137-142
105. Nagatsu T, Mogi M, Ichinose H, Togari A, Riedere P (1999) Cytokines in Parkinson's disease. Neuro Sci News 2: 88-90
106. Nagatsu T, Mogi M, Ichinose H, Togari A (2000a) Cytokines in Parkinson's disease. J Neural Transm [Suppl 58]: 143-151
107. Nagatsu T, Mogi M, Ichinose H, Togari A (2000b) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm [Suppl 60]: 277-290
108. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson's disease: Role for cytokines. Current Pharmaceutical Design 11: 999-1016
109. Nakano T, Nagatsu T, Higashida H (1985) Expression of A and B types of monoamine oxidase in differentiated neuroblastoma hybrid cells. J Neurochem 44: 755-759
110. Nakano T, Saito S, Higashida H, Kojima K, Nagatsu T (1986) Assignment of A and B types of monoamine oxidase in NCB 20 hybrid cells to those of the parental hybrid cells. J Neurochem 46: 686-694
111. Naoi M, Maruyama Y, Dostert P, Hashizume Y, Nakahara D, Takahashi T, Ota M (1996) Dopamine-derived endogenous 1(R), 2(N)-dimethyl-1,2,3,4- tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rats: Biochemical, pathological and behavioral studies. Brain Res 709: 285-295
112. Nicotra A, Parvez SH, Glover V, Sandler M, Parvez S, Minami M, eds (2004) Monoamine oxidases: molecular, pharmacological and neurotoxicological aspects, Elsevier, Amsterdam, pp 1-335
113. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Yoshida M, Dostert P, Naoi M, Nagatsu T (1993) Presence of tetrahydroisoquinoline-related compounds, possible MPTP-like neurotoxins, in Parkinsonian brain. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Parkinson's disease: From basic research to treatment. Adv Neurol Vol. 60, Raven Press, New York, pp 234-237
114. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson's dieease. Ann Neurol 38: 771-777
115. Olanow CW, Riederer P (1996) Selegiline and neuroprotection in Parkinson's disease. Neurology 47 [Suppl 3]: 137-216
116. Oleland L (2004) Platelet monoamine oxidase, personality and alcoholism: rise, fall and resurrection. Neuro Toxicology 25: 79-89
117. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson's disease. Arch Neurol 59: 1937-1943
118. Pintar JE, Barbosa J, Francke U, Castiglione CM Jr, Hawkins M, Breakfield XO (1981) Gene for monoamine oxidase type A assigned to the human X chromosome. J Neurosci 1: 166-175
119. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadoce A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, DiIoro G, Globe LI, Nussbaum RL (1998) Mutation in the alpha-synuclein gene idetifies in families with Parkinson's disease. Science 276: 2045-2047
120. Powell JF, Huang RH, Breakefield XO, Craig I, Hsu YPP (1991) Structure of the human gene for monoamine oxidase type A. Nucleic Acids Res 19: 4537-4541
121. Riederer P, Youdim MBH, eds (1990) Amine oxidases and their impact on neurobiology. J Neural Transm [Suppl 32]: 1-491
122. Riederer P, Lachenmayer L (2003) Selegiline's neuroprotective capacity revisited. J Neural Transm 110: 1273-1278
123. Sandler M, Bonham-Carter S, Hunter KR, Stern GM (1973) Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-DOPA in man. Nature 241: 439-443
124. Saura J, Richards JG, Mahy N (1994) Age-related changes in MAO in B1/C57 mouse tissues: a quantitative radioautography study. J Neural Transm 41: 89-94
125. Sawada M, Imamura K, Nagatsu T (2005) Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm: in press
126. Schnaitman C, Erwin VG, Greenwalt JW (1967) The submitochondrial localization of monoamine oxidase. An enzymeatic marker for the outer membrane of rat liver mitochondria. J Cell Biol 32: 719-735
127. Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315: 19-30
128. Shih JC, Chen K, Geha RM (1998) Determination of regions important for monoamine oxidase (MAO) A and B substrate and inhibitor selectivities. J Neural Transm [Suppl 52]: 1-8
129. Shih JC, Chen JC, Ridd MJ (1999) Monoamine oxidase: from gene to behavior. Ann Rev Neurosci 22: 197-217
130. Shih JC (2004) Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B. Neuro Toxicology 25: 21-30
131. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa A, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet 25: 302-305
132. Sofic E, Riederer P, Heisen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Incresed iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199-205
133. Takahata K, Minami A, Kusumoto H, Schimizu S, Yoneda F (2005a) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518: 140-144
134. Takahata K, Shimizu S, Katsuki H, Yoneda F, Akaike A (2005b) Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm On-line publication, 15 June 2005
135. Tatton W, Chalmers-Redman R, Tatton N (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehydes-3-phosphate dehydrogenase rather than monoamone oxidase B. J Neural Transm 110: 509-515
136. The Parkinson Study Group (1989) Effects of deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 321: 1364-1371
137. The Parkinson Study Group (1993) Effects of tocophrol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med 328: 176-183
138. Tipton KF (1980) Monoamine oxidase. In: Jakoby WB (ed) Enzymatic basis of detoxication Vol. 1. Academic Press, New York, pp 355-370
139. Tsugeno Y, Hirashiki I, Ogata F, Ito A (1995) Regions of the molecule responsible for substrate specificity of monoamine oxidase A and B: a chimeric enzyme analysis. J Biochem 118: 974-980
140. Tsugeno Y, Ito A (1997) A key amino acid responsible for substrate selectivity of monoamine oxidase A and B. J Biol Chem 272: 14033-14036
141. Vilhardt F, Piastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, Trono D, Krause K-H (2002) The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 277: 42136-42143
142. Walker WH, Kearney EB, Seng RL, Singer TP (1971) Sequence and structure of a cysteinyl flavin peptide from monoamine oxidase. Biochem Biophys Res Commun 44: 287-292
143. Westlund KN, Denney RM, Rose RM, Abell CW (1988a) Localization of distinct monoamine oxidase A and monoamine oxidase B in rat brain. J Neural Transm 74: 29-42
144. Westlund KN, Denney RM, Rose RM, Abell CW (1988b) Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439-456
145. Weyler W (1989) Monoamine oxidase A from human placenta and monoamine oxidase from bovine liver both have one FAD per subunit. An important revision. Biochem J 260: 726-729
146. Weyler W, Hsu YPP, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmac Ther 47: 391-417
147. Willonghby J, Glover V, Sandler M (1988) Histochemical localization of monoamine oxidase A and B in rat brain. J Neural Transm 74: 29-42
148. Youdim BH, Riederer P (1997) Understanding Parkinson's disease. Sci Amer: 82-89
149. Youdim MBH, Ben-Shachter D, Eshel G, Finberg JPM, Riederer P (1993) The neurotoxicity of iron and nitric oxide: Relevance to etiology of Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Parkinson's disease: From basic research to treatment. Adv Neurol Vol. 60, Raven Press, New York, 259-266
150. Youdim MBH, Tipton KF (2002) Rat striatal monoamine oxidase-B inhibition by 1-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord 8: 247-253
151. Youdim MBH, Fridkin M, Zheng H (2004) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 111: 1455-1471
152. Youdim MBH, Maruyama W, Naoi M (2005) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiperkinsonian drug, rasagiline. Drugs of Today 41: on line publication
153. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong J-S, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19: 533-542